RxDoctor Payments Data

Ebenezer Oni, MD

Internal Medicine · West Reading, PANPI 1215325238

Payments from drug & device makers

$5,217in general payments, 2019–2025

Across 271 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Astellas Pharma US Inc$479
  • Pfizer$391
  • Impulse Dynamics (USA) Inc.$384
  • Johnson & Johnson$173
  • AstraZeneca$164
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,65289%
  • Education$56511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,217 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$154,797
Medicare patients
1,640
Services billed
2,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$57,822
EntrestoSacubitril/Valsartan27$28,291
BrilintaTicagrelor17$12,207
Atorvastatin Calcium110$1,569
Metoprolol Succinate111$1,471
Amlodipine Besylate84$721
Ezetimibe20$662
Valsartan11$576
Amiodarone Hcl17$564
Lisinopril37$393
ClopidogrelClopidogrel Bisulfate28$368
Rosuvastatin Calcium24$349
Carvedilol32$349
Furosemide52$323
Isosorbide Mononitrate ErIsosorbide Mononitrate24$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$391$57,82249 claims
NovartisEntresto$103$28,29127 claims
AstraZenecaBrilinta$164$12,20717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in West Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →